MIH
HEPA

Meitav Investment House’s Hepion Pharmaceuticals HEPA Stock Holding History

Meitav Investment House’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$99K – 423
2021
Q2 		$99K Buy
50
+6
+14% +$11K ﹤0.01% 402
2021
Q1 		$81 Buy
+44
New +$96.5K ﹤0.01% 370

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Meitav Investment House's HEPA Position: Q3 2021 in Review

Meitav Investment House sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 50 shares — an estimated $99K sold.

Meitav Investment House first reported a position in HEPA in Q1 2021 and held it in 2 quarters. The position peaked at $99K in Q2 2021. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Meitav Investment House reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Meitav Investment House sold 50 Hepion Pharmaceuticals shares in Q3 2021, an estimated $99K.
  • Meitav Investment House first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Meitav Investment House's Hepion Pharmaceuticals position peaked at $99K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Meitav Investment House's 13F filing for Q3 2021, filed 3 Nov 2021.